You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Biosimilars in Multiple Sclerosis: Entering a New Era of Biologic Therapy

  • Authors: Per Soelberg Sørensen, MD, DMSc, FEAN, FAAN; Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP; Peter Taylor, MA, BM, BCh, PhD, FRCP, FRCPE; Christian K. Schneider, MD
  • CPD Released: 3/29/2023
  • Valid for credit through: 3/29/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for an international audience of neurologists in the United States and outside the United States.

The goal of this activity is for learners to be better able to discuss the need for biosimilars in multiple sclerosis (MS) treatment and the basic science behind them.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Basic science of complex protein-based medicines
    • Analytical assessment of biologics and biosimilars
    • Production and regulatory approval process for biosimilar products


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Moderator

  • Per Soelberg Sørensen, MD, DMSc, FEAN, FAAN

    Emeritus Professor of Neurology
    Senior Consultant
    Danish Multiple Sclerosis Center
    Department of Neurology
    Copenhagen University Hospital
    Rigshospitalet
    Copenhagen, Denmark

    Disclosures

    Per Soelberg Sørensen, MD, DMSc, FEAN, FAAN, has the following relevant financial relationships:
    Consultant or advisor for: Novartis
    Speaker or member of speakers bureau for: Merck; Novartis; Teva
    Other: Chairman of Independent Data Monitoring Committee for Merck

Faculty

  • Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP

    Cancer Epidemiology, Prevention & Control Program
    Division of Public Health Sciences
    Fred Hutchinson Cancer Center
    Adjunct Professor of Public Health University of Washington
    Seattle, Washington, United States

    Disclosures

    Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Beyond Spring; Frensenius Kabi; G1 Therapeutics; Sandoz
    Research funding from: Amgen Inc.

  • Peter Taylor, MA, BM, BCh, PhD, FRCP, FRCPE

    Norman Collisson Chair of Musculoskeletal Sciences at the University of Oxford
    Botnar Research Centre
    Oxford, United Kingdom

    Disclosures

    Peter Taylor, MA, BM, BCh, PhD, FRCP, FRCPE, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Biogen; Fresenius Kabi; Galapagos; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen; Eli Lilly and Company; Pfizer Inc.; Roche; Sanofi; Nordic Pharma; UCB Pharma, Inc.
    Speaker or member of speakers bureau for: AbbVie Inc.
    Research funding from: Galapagos

  • Christian K. Schneider, MD

    Head of Biopharma Excellence
    Chief Medical Officer (Biopharma)
    PharmaLex A/S
    Hørsholm, Denmark

    Disclosures

    Christian K. Schneider, MD, has no relevant financial relationships.

Editor

  • Maya Khalaf, MSc

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Maya Khalaf, MSc, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Biosimilars in Multiple Sclerosis: Entering a New Era of Biologic Therapy

Authors: Per Soelberg Sørensen, MD, DMSc, FEAN, FAAN; Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP; Peter Taylor, MA, BM, BCh, PhD, FRCP, FRCPE; Christian K. Schneider, MDFaculty and Disclosures

CPD Released: 3/29/2023

Valid for credit through: 3/29/2024, 11:59 PM EST

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Introduction: The Advent of Biosimilars in Multiple Sclerosis

How has the introduction of biosimilars led to more affordable healthcare?
Per Soelberg Sørensen, MD, DMSc, FEAN, FAAN

What Are Biologics?

What is the inherent variability of biologics and how are they developed?

What are Biosimilars?

How do biosimilars differ from their reference biological medicines and small molecules?
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP

Originator and Biosimilar: Development Steps and Goals

Why do analytic studies matter in the development of biosimilars?
Peter Taylor, MA, BM, BCh, PhD, FRCP, FRCPE

What Is the Regulatory Approval Process for Biosimilars and Biologics?

How is clinical equivalence established between a biosimilar and its reference medicine?
Christian K. Schneider, MD
 

Educational Impact Challenge

The goal of this activity is for learners to be better able to discuss the need for biosimilars in multiple sclerosis (MS) treatment and the basic science behind them.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print